Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
← catalyst calendarNCT07227818 · readout ≤ 1,076 d
Sponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
560estimated
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-16 | actual | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Interventions
- Drug: NBI-1117568
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime From Randomization to Relapse
measured Up to approximately 30 weeks
Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed